[Integrase inhibition].
Bogner
Johannes R
JR
Infektionsabteilung, Medizinische Poliklinik, Klinikum der Universität München. johannes.bogner@med.uni-muenchen.de
D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D024921:Drug Resistance, Multiple, Viral; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D019428:HIV Integrase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D011760:Pyrrolidinones / Q000009:adverse effects / Q000627:therapeutic use; D000068898:Raltegravir Potassium
D019380:Anti-HIV Agents; D019428:HIV Integrase Inhibitors; D011760:Pyrrolidinones; D000068898:Raltegravir Potassium